Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Fairfax, B P ^a   Pratap, S ^a   Roberts, I S D ^d   Collier, J ^d   Kaplan, R ^b   Meade, A M ^b   Ritchie, A W ^b   Eisen, T ^c   Macaulay, V M ^a   Protheroe, A ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c Cambridge Biomedical Research Centre   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; DILI; Hepatotoxicity; RCC; Sorafenib; SORCE

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BISOPROLOL; CEFTRIAXONE; CREATININE; FELODIPINE; SORAFENIB;

ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPSY; BLOOD ANALYSIS; BLOOD CULTURE; BRAIN DISEASE; CANCER MORTALITY; CASE REPORT; CONTINUOUS HEMOFILTRATION; DETERIORATION; DIARRHEA; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER FAILURE; MALAISE; MALE; MEDICAL HISTORY; METASTASIS FREE SURVIVAL; MOUTH ULCER; NEPHRECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; TOXIC HEPATITIS; TUMOR VOLUME;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; FATAL OUTCOME; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84870656356     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-590     Document Type: Article

References (20)

1. Leibovich BC, Blute ML, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671. 10.1002/cncr.11234, 12655523.
2. Escudier B, Eisen T, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. 10.1056/NEJMoa060655, 17215530.
3. Escudier B, Szczylik C, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289. 10.1200/JCO.2008.19.3342, 19171708.
4. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - i. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1323-1330. 10.1016/0895-4356(93)90101-6, 8229110.
5. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009, 62:481-492. 10.1136/jcp.2008.058248, 19474352.
6. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009, 58:1555-1564. 10.1136/gut.2008.163675, 19834119.
7. Gupta-Abramson V, Troxel AB, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719. 10.1200/JCO.2008.16.3279, 2653134, 18541894.
8. Schramm C, Schuch G, et al. Sorafenib-induced liver failure. Am J Gastroenterol 2008, 103:2162-2163.
9. Llanos L, Bellot P, et al. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. Am J Gastroenterol 2009, 104:257-258. 10.1038/ajg.2008.41, 19098892.
10. Herden U, Fischer L, et al. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation 2010, 90(1):98-99. 10.1097/TP.0b013e3181daac69, 20606568.
11. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010, 11(5):607-611. 10.2217/pgs.10.24, 20415545.
12. Daly AK, Donaldson PT, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819. 10.1038/ng.379, 19483685.
13. Donaldson PT, Daly AK, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010, 53(6):1049-1053. 10.1016/j.jhep.2010.05.033, 20800921.
14. O'Donohue J, Oien KA, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000, 47:717-720. 10.1136/gut.47.5.717, 1728095, 11034591.
15. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR. HLA-DQA1*0201 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011, 29(6):667-73. 10.1200/JCO.2010.31.3197, 21245432.
16. Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, Koshy B, Spraggs CF, Mooser VE, Cardon LR, Pandite LN. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 2011, 54(6):1237-43. 10.1016/j.jhep.2010.09.028, 21145803.
17. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006, 43(3):618-631. 10.1002/hep.21095, 16496329.
18. Llovet JM, Ricci S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390. 10.1056/NEJMoa0708857, 18650514.
19. Cheng AL, Kang YK, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
20. Dilthey AT, Moutsianas L, Leslie S, McVean G. HLA*IMP-an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinformatics 2011, 27:968-972. 10.1093/bioinformatics/btr061, 3065693, 21300701.